Regenerative Medicine (RM) is a rapidly expanding set of innovative medical technologies that restore function by enabling the body to repair, replace, and regenerate damaged, aging or diseased cells, tissues and organs.

Regenerative therapies have been demonstrated (in trials or the laboratory) to heal broken bones, treat severe burns, blindness, deafness, heart damage, nerve damage, Parkinson's, diabetes and other conditions. Significant momentum has been achieved in recent years as evidenced by the surge in government and foundation research funding, 175,000+ peer-reviewed publications, 10,000+ issued/pending patents, and 800+ FDA-approved clinical trials for RM. This, in turn, has led to a proliferation of patient advocacy groups rightfully demanding a shift in medical treatment paradigms from "bandaid therapies" to prevention, cure, rejuvenation, restoration, and replacement.

Savvy entrepreneurs and passionate physicians and scientists are joining forces to take on the challenge of translating this innovative research into revolutionary medical therapies capable of alleviating the tremendous healthcare burden experienced by developed and developing countries worldwide. There now 300+ private and 30+ public companies fueled in part by discovery work at over 65 academic programs. The current market for RM is $5.5B, and is projected to reach $11.5B in 2010, yielding a CAGR of 27.5%. With DHHS predicting the market for RM will reach $300B by 2020, it's no surprise that many analysts feel the sector is now entering into the inflection phase of the Garnter Curve for what some are calling "the internet of healthcare."

It is the mission of Proteus Venture Partners to transform healthcare through regenerative medicine, capitalizing on the convergence of key market factors including: an ever-aging population, diminishing Big Pharma pipelines, and significant corporate investment (eg. PerkinElmer's recent acquisition of ViaCell for $300M, Genzyme's acquisition of AnorMed for $580M, and Medtronic's $135M joint venture with Genzyme). In this quest towards commercialization, Proteus Venture Partners has assembled the brightest minds in the field and built an elite team capable of providing the capital, scientific insight, and business leadership to launch and support the most successful RM companies in the world. Proteus Venture Partners will execute its mission by employing its proprietary deal flow and due diligence algorithms, an active management philosophy, and 50+ years of exit strategy experience through licensing deals, M&A transactions, and public offerings.